Does the media refer more to TECX or ADCT?

In the previous week, Tectonic Therapeutic had 1 more articles in the media than ADC Therapeutics. MarketBeat recorded 2 mentions for Tectonic Therapeutic and 1 mentions for ADC Therapeutics. ADC Therapeutics' average media sentiment score of 0.84 beat Tectonic Therapeutic's score of 0.83 indicating that ADC Therapeutics is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Tectonic Therapeutic 0 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive ADC Therapeutics 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Does the media favor PRME or ADCT?

In the previous week, Prime Medicine had 3 more articles in the media than ADC Therapeutics. MarketBeat recorded 4 mentions for Prime Medicine and 1 mentions for ADC Therapeutics. ADC Therapeutics' average media sentiment score of 0.84 beat Prime Medicine's score of 0.81 indicating that ADC Therapeutics is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Prime Medicine 3 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive ADC Therapeutics 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Does the media favor CTMX or ADCT?

In the previous week, CytomX Therapeutics had 10 more articles in the media than ADC Therapeutics. MarketBeat recorded 11 mentions for CytomX Therapeutics and 1 mentions for ADC Therapeutics. CytomX Therapeutics' average media sentiment score of 1.24 beat ADC Therapeutics' score of 0.84 indicating that CytomX Therapeutics is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment CytomX Therapeutics 8 Very Positive mention(s) 0 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive ADC Therapeutics 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Does the media favor RLMD or ADCT?

In the previous week, Relmada Therapeutics had 8 more articles in the media than ADC Therapeutics. MarketBeat recorded 9 mentions for Relmada Therapeutics and 1 mentions for ADC Therapeutics. Relmada Therapeutics' average media sentiment score of 1.29 beat ADC Therapeutics' score of 0.84 indicating that Relmada Therapeutics is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Relmada Therapeutics 6 Very Positive mention(s) 1 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive ADC Therapeutics 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Does the media refer more to ADCT or NGNE?

In the previous week, Neurogene had 1 more articles in the media than ADC Therapeutics. MarketBeat recorded 2 mentions for Neurogene and 1 mentions for ADC Therapeutics. Neurogene's average media sentiment score of 1.16 beat ADC Therapeutics' score of 0.84 indicating that Neurogene is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment ADC Therapeutics 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Neurogene 1 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

ADC Therapeutics (ADCT) Competitors

$1.03 -0.02 (-1.43%)

As of 12:51 PM Eastern

Compare

ADCT vs. TECX, PRME, CTMX, RLMD, and NGNE

Should you buy ADC Therapeutics stock or one of its competitors? MarketBeat compares ADC Therapeutics with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with ADC Therapeutics include Tectonic Therapeutic (TECX), Prime Medicine (PRME), CytomX Therapeutics (CTMX), Relmada Therapeutics (RLMD), and Neurogene (NGNE).

How does ADC Therapeutics compare to Tectonic Therapeutic?

Tectonic Therapeutic (NASDAQ:TECX) and ADC Therapeutics (NYSE:ADCT) are both small-cap healthcare companies, but which is the better stock? We will compare the two companies based on the strength of their dividends, earnings, analyst recommendations, risk, media sentiment, profitability, valuation and institutional ownership.

Tectonic Therapeutic presently has a consensus target price of $79.40, indicating a potential upside of 186.54%. ADC Therapeutics has a consensus target price of $6.25, indicating a potential upside of 503.86%. Given ADC Therapeutics' higher possible upside, analysts plainly believe ADC Therapeutics is more favorable than Tectonic Therapeutic.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Tectonic Therapeutic	2 Sell rating(s)	0 Hold rating(s)	4 Buy rating(s)	2 Strong Buy rating(s)	2.75
ADC Therapeutics	1 Sell rating(s)	2 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.33

Tectonic Therapeutic has higher earnings, but lower revenue than ADC Therapeutics. Tectonic Therapeutic is trading at a lower price-to-earnings ratio than ADC Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Tectonic Therapeutic	N/A	N/A	-$74.15M	-$4.46	N/A
ADC Therapeutics	$79.18M	1.66	-$142.62M	-$1.05	N/A

62.6% of Tectonic Therapeutic shares are held by institutional investors. Comparatively, 41.1% of ADC Therapeutics shares are held by institutional investors. 39.8% of Tectonic Therapeutic shares are held by company insiders. Comparatively, 5.4% of ADC Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock is poised for long-term growth.

Tectonic Therapeutic has a net margin of 0.00% compared to ADC Therapeutics' net margin of -173.02%. ADC Therapeutics' return on equity of 0.00% beat Tectonic Therapeutic's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Tectonic Therapeutic	N/A	-32.33%	-30.92%
ADC Therapeutics	-173.02%	N/A	-44.70%

Tectonic Therapeutic has a beta of 3.21, suggesting that its stock price is 221% more volatile than the broader market. Comparatively, ADC Therapeutics has a beta of 1.87, suggesting that its stock price is 87% more volatile than the broader market.

In the previous week, Tectonic Therapeutic had 1 more articles in the media than ADC Therapeutics. MarketBeat recorded 2 mentions for Tectonic Therapeutic and 1 mentions for ADC Therapeutics. ADC Therapeutics' average media sentiment score of 0.84 beat Tectonic Therapeutic's score of 0.83 indicating that ADC Therapeutics is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Tectonic Therapeutic	0 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
ADC Therapeutics	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Summary

Tectonic Therapeutic beats ADC Therapeutics on 10 of the 16 factors compared between the two stocks.

How does ADC Therapeutics compare to Prime Medicine?

Prime Medicine (NASDAQ:PRME) and ADC Therapeutics (NYSE:ADCT) are both small-cap healthcare companies, but which is the superior business? We will compare the two businesses based on the strength of their analyst recommendations, earnings, institutional ownership, profitability, dividends, media sentiment, valuation and risk.

Prime Medicine has a beta of 2.31, indicating that its stock price is 131% more volatile than the broader market. Comparatively, ADC Therapeutics has a beta of 1.87, indicating that its stock price is 87% more volatile than the broader market.

Prime Medicine presently has a consensus target price of $7.53, indicating a potential upside of 166.59%. ADC Therapeutics has a consensus target price of $6.25, indicating a potential upside of 503.86%. Given ADC Therapeutics' higher possible upside, analysts clearly believe ADC Therapeutics is more favorable than Prime Medicine.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Prime Medicine	1 Sell rating(s)	0 Hold rating(s)	6 Buy rating(s)	1 Strong Buy rating(s)	2.88
ADC Therapeutics	1 Sell rating(s)	2 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.33

ADC Therapeutics has higher revenue and earnings than Prime Medicine. Prime Medicine is trading at a lower price-to-earnings ratio than ADC Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Prime Medicine	$4.63M	110.21	-$201.14M	-$1.23	N/A
ADC Therapeutics	$79.18M	1.66	-$142.62M	-$1.05	N/A

ADC Therapeutics has a net margin of -173.02% compared to Prime Medicine's net margin of -4,917.55%. ADC Therapeutics' return on equity of 0.00% beat Prime Medicine's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Prime Medicine	-4,917.55%	-188.82%	-60.97%
ADC Therapeutics	-173.02%	N/A	-44.70%

70.4% of Prime Medicine shares are held by institutional investors. Comparatively, 41.1% of ADC Therapeutics shares are held by institutional investors. 16.0% of Prime Medicine shares are held by company insiders. Comparatively, 5.4% of ADC Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock is poised for long-term growth.

In the previous week, Prime Medicine had 3 more articles in the media than ADC Therapeutics. MarketBeat recorded 4 mentions for Prime Medicine and 1 mentions for ADC Therapeutics. ADC Therapeutics' average media sentiment score of 0.84 beat Prime Medicine's score of 0.81 indicating that ADC Therapeutics is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Prime Medicine	3 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
ADC Therapeutics	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Summary

ADC Therapeutics beats Prime Medicine on 9 of the 17 factors compared between the two stocks.

How does ADC Therapeutics compare to CytomX Therapeutics?

CytomX Therapeutics (NASDAQ:CTMX) and ADC Therapeutics (NYSE:ADCT) are both small-cap healthcare companies, but which is the better investment? We will compare the two companies based on the strength of their analyst recommendations, institutional ownership, earnings, dividends, media sentiment, profitability, risk and valuation.

CytomX Therapeutics has a beta of 2.12, indicating that its stock price is 112% more volatile than the broader market. Comparatively, ADC Therapeutics has a beta of 1.87, indicating that its stock price is 87% more volatile than the broader market.

In the previous week, CytomX Therapeutics had 10 more articles in the media than ADC Therapeutics. MarketBeat recorded 11 mentions for CytomX Therapeutics and 1 mentions for ADC Therapeutics. CytomX Therapeutics' average media sentiment score of 1.24 beat ADC Therapeutics' score of 0.84 indicating that CytomX Therapeutics is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
CytomX Therapeutics	8 Very Positive mention(s)	0 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
ADC Therapeutics	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

67.8% of CytomX Therapeutics shares are owned by institutional investors. Comparatively, 41.1% of ADC Therapeutics shares are owned by institutional investors. 3.8% of CytomX Therapeutics shares are owned by insiders. Comparatively, 5.4% of ADC Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock is poised for long-term growth.

CytomX Therapeutics currently has a consensus price target of $12.10, indicating a potential upside of 287.20%. ADC Therapeutics has a consensus price target of $6.25, indicating a potential upside of 503.86%. Given ADC Therapeutics' higher probable upside, analysts plainly believe ADC Therapeutics is more favorable than CytomX Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
CytomX Therapeutics	1 Sell rating(s)	0 Hold rating(s)	9 Buy rating(s)	2 Strong Buy rating(s)	3.00
ADC Therapeutics	1 Sell rating(s)	2 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.33

CytomX Therapeutics has higher earnings, but lower revenue than ADC Therapeutics. CytomX Therapeutics is trading at a lower price-to-earnings ratio than ADC Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
CytomX Therapeutics	$76.20M	6.98	-$17.37M	-$0.41	N/A
ADC Therapeutics	$79.18M	1.66	-$142.62M	-$1.05	N/A

CytomX Therapeutics has a net margin of -166.40% compared to ADC Therapeutics' net margin of -173.02%. ADC Therapeutics' return on equity of 0.00% beat CytomX Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
CytomX Therapeutics	-166.40%	-36.61%	-28.02%
ADC Therapeutics	-173.02%	N/A	-44.70%

Summary

CytomX Therapeutics beats ADC Therapeutics on 12 of the 17 factors compared between the two stocks.

How does ADC Therapeutics compare to Relmada Therapeutics?

Relmada Therapeutics (NASDAQ:RLMD) and ADC Therapeutics (NYSE:ADCT) are both small-cap healthcare companies, but which is the better stock? We will contrast the two companies based on the strength of their analyst recommendations, institutional ownership, earnings, valuation, profitability, risk, media sentiment and dividends.

45.2% of Relmada Therapeutics shares are owned by institutional investors. Comparatively, 41.1% of ADC Therapeutics shares are owned by institutional investors. 14.5% of Relmada Therapeutics shares are owned by insiders. Comparatively, 5.4% of ADC Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company is poised for long-term growth.

In the previous week, Relmada Therapeutics had 8 more articles in the media than ADC Therapeutics. MarketBeat recorded 9 mentions for Relmada Therapeutics and 1 mentions for ADC Therapeutics. Relmada Therapeutics' average media sentiment score of 1.29 beat ADC Therapeutics' score of 0.84 indicating that Relmada Therapeutics is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Relmada Therapeutics	6 Very Positive mention(s)	1 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
ADC Therapeutics	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Relmada Therapeutics has higher earnings, but lower revenue than ADC Therapeutics. Relmada Therapeutics is trading at a lower price-to-earnings ratio than ADC Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Relmada Therapeutics	N/A	N/A	-$57.38M	-$1.09	N/A
ADC Therapeutics	$79.18M	1.66	-$142.62M	-$1.05	N/A

Relmada Therapeutics presently has a consensus target price of $12.00, indicating a potential upside of 132.33%. ADC Therapeutics has a consensus target price of $6.25, indicating a potential upside of 503.86%. Given ADC Therapeutics' higher possible upside, analysts clearly believe ADC Therapeutics is more favorable than Relmada Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Relmada Therapeutics	1 Sell rating(s)	1 Hold rating(s)	5 Buy rating(s)	1 Strong Buy rating(s)	2.75
ADC Therapeutics	1 Sell rating(s)	2 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.33

Relmada Therapeutics has a beta of 0.41, indicating that its share price is 59% less volatile than the broader market. Comparatively, ADC Therapeutics has a beta of 1.87, indicating that its share price is 87% more volatile than the broader market.

Relmada Therapeutics has a net margin of 0.00% compared to ADC Therapeutics' net margin of -173.02%. ADC Therapeutics' return on equity of 0.00% beat Relmada Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Relmada Therapeutics	N/A	-71.22%	-64.46%
ADC Therapeutics	-173.02%	N/A	-44.70%

Summary

Relmada Therapeutics beats ADC Therapeutics on 9 of the 16 factors compared between the two stocks.

How does ADC Therapeutics compare to Neurogene?

ADC Therapeutics (NYSE:ADCT) and Neurogene (NASDAQ:NGNE) are both small-cap healthcare companies, but which is the better business? We will compare the two companies based on the strength of their institutional ownership, profitability, analyst recommendations, media sentiment, valuation, earnings, risk and dividends.

ADC Therapeutics has a beta of 1.87, meaning that its share price is 87% more volatile than the broader market. Comparatively, Neurogene has a beta of 1.7, meaning that its share price is 70% more volatile than the broader market.

ADC Therapeutics currently has a consensus price target of $6.25, indicating a potential upside of 503.86%. Neurogene has a consensus price target of $84.83, indicating a potential upside of 156.13%. Given ADC Therapeutics' higher possible upside, equities research analysts plainly believe ADC Therapeutics is more favorable than Neurogene.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
ADC Therapeutics	1 Sell rating(s)	2 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.33
Neurogene	1 Sell rating(s)	0 Hold rating(s)	3 Buy rating(s)	2 Strong Buy rating(s)	3.00

Neurogene has lower revenue, but higher earnings than ADC Therapeutics. Neurogene is trading at a lower price-to-earnings ratio than ADC Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
ADC Therapeutics	$79.18M	1.66	-$142.62M	-$1.05	N/A
Neurogene	$930K	562.70	-$90.35M	-$4.55	N/A

41.1% of ADC Therapeutics shares are held by institutional investors. Comparatively, 52.4% of Neurogene shares are held by institutional investors. 5.4% of ADC Therapeutics shares are held by company insiders. Comparatively, 11.7% of Neurogene shares are held by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth.

Neurogene has a net margin of 0.00% compared to ADC Therapeutics' net margin of -173.02%. ADC Therapeutics' return on equity of 0.00% beat Neurogene's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
ADC Therapeutics	-173.02%	N/A	-44.70%
Neurogene	N/A	-37.88%	-34.70%

In the previous week, Neurogene had 1 more articles in the media than ADC Therapeutics. MarketBeat recorded 2 mentions for Neurogene and 1 mentions for ADC Therapeutics. Neurogene's average media sentiment score of 1.16 beat ADC Therapeutics' score of 0.84 indicating that Neurogene is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
ADC Therapeutics	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Neurogene	1 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Summary

Neurogene beats ADC Therapeutics on 10 of the 16 factors compared between the two stocks.

Get ADC Therapeutics News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding ADCT and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NYSE and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

ADCT vs. The Competition

Export

Metric	ADC Therapeutics	Biotechnology Industry	Healthcare Sector	NYSE Exchange
Market Cap	$132.92M	$3.52B	$6.80B	$23.74B
Dividend Yield	N/A	3.78%	2.59%	4.21%
P/E Ratio	-1.00	7.38	282.16	31.39
Price / Sales	1.66	1,220.59	576.18	165.39
Price / Cash	N/A	44.80	28.60	18.73
Price / Book	-0.69	16.79	10.96	4.81
Net Income	-$142.62M	-$12.56M	$3.49B	$1.07B
7 Day Performance	-8.81%	-0.84%	0.45%	0.71%
1 Month Performance	-14.11%	-7.59%	-4.26%	0.47%
1 Year Performance	-61.81%	49.20%	63.09%	20.41%

ADC Therapeutics Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
ADCT ADC Therapeutics	3.5825 of 5 stars	$1.04 -1.4%	$6.25 +503.9%	-61.3%	$132.92M	$79.18M	N/A	310
TECX Tectonic Therapeutic	3.3672 of 5 stars	$29.77 -2.7%	$79.40 +166.7%	+35.2%	$562.11M	N/A	N/A	120	Upcoming Earnings
PRME Prime Medicine	3.414 of 5 stars	$2.99 -0.8%	$7.53 +152.3%	N/A	$540.96M	$4.63M	N/A	N/A	News Coverage
CTMX CytomX Therapeutics	2.6461 of 5 stars	$3.19 -2.0%	$12.10 +279.9%	+31.9%	$540.35M	$76.20M	N/A	170	News Coverage Positive News Upcoming Earnings
RLMD Relmada Therapeutics	2.3284 of 5 stars	$5.12 -1.5%	$12.00 +134.4%	+799.4%	$539.66M	N/A	N/A	10	Positive News Upcoming Earnings

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NYSE:ADCT) was last updated on 8/3/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

ADC Therapeutics (ADCT) Competitors

ADCT vs. TECX, PRME, CTMX, RLMD, and NGNE

How does ADC Therapeutics compare to Tectonic Therapeutic?

Summary

How does ADC Therapeutics compare to Prime Medicine?

Summary

How does ADC Therapeutics compare to CytomX Therapeutics?

Summary

How does ADC Therapeutics compare to Relmada Therapeutics?

Summary

How does ADC Therapeutics compare to Neurogene?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

ADCT vs. The Competition

ADC Therapeutics Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

ADC Therapeutics (ADCT) Competitors

ADCT vs. TECX, PRME, CTMX, RLMD, and NGNE

How does ADC Therapeutics compare to Tectonic Therapeutic?

Do analysts recommend TECX or ADCT?

Which has higher valuation and earnings, TECX or ADCT?

Do institutionals & insiders have more ownership in TECX or ADCT?

Is TECX or ADCT more profitable?

Which has more volatility & risk, TECX or ADCT?

Does the media refer more to TECX or ADCT?

Summary

How does ADC Therapeutics compare to Prime Medicine?

Which has more risk and volatility, PRME or ADCT?

Do analysts recommend PRME or ADCT?

Which has better valuation and earnings, PRME or ADCT?

Is PRME or ADCT more profitable?

Do institutionals and insiders believe in PRME or ADCT?

Does the media favor PRME or ADCT?

Summary

How does ADC Therapeutics compare to CytomX Therapeutics?

Which has more risk & volatility, CTMX or ADCT?

Does the media favor CTMX or ADCT?

Do insiders and institutionals believe in CTMX or ADCT?

Do analysts recommend CTMX or ADCT?

Which has higher earnings & valuation, CTMX or ADCT?

Is CTMX or ADCT more profitable?

Summary

How does ADC Therapeutics compare to Relmada Therapeutics?

Do insiders & institutionals believe in RLMD or ADCT?

Does the media favor RLMD or ADCT?

Which has preferable earnings and valuation, RLMD or ADCT?

Do analysts recommend RLMD or ADCT?

Which has more volatility & risk, RLMD or ADCT?

Is RLMD or ADCT more profitable?

Summary

How does ADC Therapeutics compare to Neurogene?

Which has more risk & volatility, ADCT or NGNE?

Do analysts rate ADCT or NGNE?

Which has better valuation & earnings, ADCT or NGNE?

Do institutionals and insiders believe in ADCT or NGNE?

Is ADCT or NGNE more profitable?

Does the media refer more to ADCT or NGNE?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

ADCT vs. The Competition

ADC Therapeutics Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools